{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:56:43Z","timestamp":1773345403176,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Intrahepatic cholangiocarcinoma (ICC) accounts for 10% to 15% of all primary hepatic carcinomas. However, there are no effective drug treatment strategies against ICC, and surgery is currently the only curative treatment. Here, we present a case of ICC successfully treated with anlotinib, a novel oral agent.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient was a 66-year-old Han Chinese woman, and she was a retired worker. The patient had no history of hepatitis B infection or hypertension. Physical examination showed no abnormalities, and the patient showed no conscious discomfort. However, ultrasound revealed liver occupation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Liver ultrasound and enhanced computed tomography (CT) indicated liver cancer with intrahepatic metastasis. Serum carbohydrate antigen 199 and alpha fetoprotein levels were high at 4270 and 1561\u200ang\/mL, respectively. Pathologic findings of CT-guided liver biopsy revealed an adenocarcinoma. Owing to further immunohistochemical staining and clinical results, a diagnosis of ICC was made.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient had received 5 cycles of transhepatic arterial chemotherapy and embolization and 1 cycle of microwave ablation. Due to rapid tumor progression and loss of liver function, systemic chemotherapy was contraindicated. As second-line therapy, she received anlotinib, a novel tyrosine kinase inhibitor that inhibits tumor angiogenesis and proliferative signaling and has been used to treat refractory advanced non-small-cell lung cancer that shows progression despite treatment with \u22652 chemotherapy regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>This patient showed a partial response after 2 cycles of treatment with anlotinib (12\u200amg daily, days 1\u201314 of a 21-day cycle). Drug-related side effects, such as hypertension and hand foot skin reaction, were observed. After 4 cycles of anlotinib, the efficacy appeared to be stable, and the patient showed a progression-free survival period of almost 4 months. However, the patient's condition worsened and she died of liver failure 6 months after treatment (overall survival, almost 6 months).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Some cases of ICC may be responsive to the antiangiogenic drug, anlotinib, when combined with microwave ablation. Randomized clinical studies are required to further confirm the efficacy and safety of anlotinib in the clinical treatment of ICC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000018435","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T20:38:40Z","timestamp":1577392720000},"page":"e18435","source":"Crossref","is-referenced-by-count":11,"title":["Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation"],"prefix":"10.1097","volume":"98","author":[{"given":"Aixia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,12]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1038\/s41419-017-0015-6","article-title":"Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma","volume":"8","author":"Xie","year":"2017","journal-title":"Cell Death Dis"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2009.11.004","article-title":"Stereotactic body radiotherapy for unresectable cholangiocarcinoma","volume":"94","author":"Kopek","year":"2010","journal-title":"Radiother Oncol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)","volume":"118","author":"Han","year":"2018","journal-title":"Br J Cancer"},{"key":"R8-20230915","first-page":"1221","article-title":"Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results","volume":"33","author":"Guido","year":"2013","journal-title":"Anticancer Res"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial","volume":"31","author":"Peng","year":"2013","journal-title":"J Clin Oncol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/gutjnl-2011-300975","article-title":"Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: a multicentre analysis of 1363 treatment-na\u00efve lesions in 1007 patients in China","volume":"61","author":"Liang","year":"2012","journal-title":"Gut"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00534-012-0527-5","article-title":"Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN)for hepatocellular carcinoma: a single center experience of 719 consecutive cases","volume":"20","author":"Takami","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1245\/s10434-011-1831-z","article-title":"Efficacy of surgical microwave therapy in patients with unresectable hepatocellular carcinoma","volume":"18","author":"Itoh","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"(3 suppl 6)","key":"R13-20230915","first-page":"1","article-title":"A multidisciplinary approach to the management of hepatocellular carcinoma","volume":"6","author":"Gish","year":"2010","journal-title":"Gastroenterol Hepatol"},{"key":"R14-20230915","first-page":"364","article-title":"Investigation on the role of VEGF gene polymorphisms in the risk of osteosarcoma","volume":"31","author":"Li","year":"2015","journal-title":"Pakistan J Med Sci"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"21775","DOI":"10.18632\/oncotarget.7982","article-title":"DSGOST inhibits tumor growth by blocking VEGF \/VEGFR2-activated angiogenesis","volume":"7","author":"Choi","year":"2016","journal-title":"Oncotarget"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/IGC.0000000000001129","article-title":"Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model","volume":"28","author":"Taurin","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"30038","DOI":"10.1038\/srep30038","article-title":"Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model","volume":"6","author":"Beedie","year":"2016","journal-title":"Sci Rep"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"(suppl)","key":"R19-20230915","first-page":"i29","article-title":"Anlontinib as third-line treatment in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomized, double-blind, placebo-controlled, phase II trial (NCT01924195)","volume":"26","author":"Han","year":"2015","journal-title":"Ann Oncol"},{"issue":"(suppl)","key":"R20-20230915","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1470-2045(17)30759-3","article-title":"Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303):a randomized, double-blind, placebo-controlled phase 3 study","volume":"18","author":"Han","year":"2017","journal-title":"Lancet Oncol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/JTO.0000000000000693","article-title":"Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: a phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens","volume":"10","author":"Paz-Ares","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/1078-0432.CCR-07-1221","article-title":"Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice","volume":"14","author":"Ogino","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:15:31Z","timestamp":1694812531000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018435"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":22,"journal-issue":{"issue":"52","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018435","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}